Probe Into GSK/Pfizer Consumer Tie-up Launched By Australian Competition Watchdog
Executive Summary
Assessing how closely GSK's brands such as Panadol compete with Pfizer brands like Robitussin is the aim of an investigation launched by Australia's Competition and Consumer Commission into the pharma giants' proposed consumer health joint venture.
You may also be interested in...
GSK Consumer In 2019: Start On Runway Toward Demerger For Deleveraging Debt
Glaxo's priority for its consumer business is regulatory approval, expected in the second half of 2019, of a JV with Pfizer announced in December so the segment will begin contributing meaningfully to GSK's growth. CEO Emma Walmsley says the JV plan with Pfizer is GSK's "most transformational announcement to date."
GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals
Big pharmas' agreement could put consumer health where Pfizer wants, entirely in its rear-view mirror, and points GSK toward what it wants, more research and development funding freed up for the pharmaceutical ingredient operations that are its chief revenue drivers. All-equity deal, giving GSK 68% control and expected to close in 2019 second half, also likely will boost investors' confidence in the firms as both have been dogged by pressure to sell, spin-off or otherwise divest their consumer businesses.
How Pfizer Achieved 'Switch Success' With Viagra and Nexium
Pfizer secured two of the biggest prescription-to-OTC switches in recent years with the reclassification of Viagra and Nexium. Michelle Riddalls, Pfizer's director of regulatory affairs in Europe, offers her advice to firms looking to emulate this 'switch success'.